Results 51 to 60 of about 31,697 (263)

Emerging Strategies for Platelet‐Modified Nanoparticles in Targeted Tumor Therapy

open access: yesAdvanced NanoBiomed Research, EarlyView.
This review highlights innovative strategies using platelet‐modified nanoparticles to target tumors more precisely. By mimicking platelet functions, these biomimetic carriers improve tumor homing, enhance drug delivery, and reduce immune clearance.
Chunyu Bai   +5 more
wiley   +1 more source

Von Willebrand Disease in the elderly: clinical perspectives

open access: yesClinical Interventions in Aging, 2018
John Chapin Department of Hematology, Shire, Lexington, MA, USA Abstract: Von Willebrand disease (VWD) is an inherited bleeding disorder that affects up to 1% of the population. In most cases, VWD results from a mutation in the von Willebrand Factor (VWF)
Chapin J
doaj  

Blood clot inspired pore‐gradient nanofiber sponge with “outer filtration” and “inner adsorption” bifunction for rapid stop of uncontrolled hemorrhage

open access: yesBMEMat, EarlyView.
In this study, by mimicking the nanofiber structure and netting blood cells function of fibrin network in blood clots, we developed a novel bioinspired quaternized chitosan nanofiber sponge with distinct blood cell filtration and blood plasma absorption bifunction for rapid hemostasis.
Fujin Zhou   +8 more
wiley   +1 more source

Clinical Application and Evaluation of Preoperative Bleeding Tendency using Platelet Function Analyzer (PFA)-100. [PDF]

open access: yesArchives of Aesthetic Plastic Surgery, 2013
Routine preoperative tests such as BT/CT, PT/PTT and CBC, could not test abnormal hemostasis that take drugs and health functional food. We used platelet function analyzer (PFA®)-100, to evaluate preoperative bleeding tendencies.
Jihu Han   +4 more
doaj   +1 more source

Haemophilia A and von Willebrand’s disease [PDF]

open access: yesHaemophilia, 2010
Summary.  Deficient or defective coagulation factor VIII (FVIII) and von Willebrand factor (VWF) can cause bleeding through congenital deficiency or acquired inhibitory antibodies. Recent studies on type 1 von Willebrand’s disease (VWD), the most common form of the disease, have begun to explain its pathogenesis.
Goodeve, A.C., Rosen, S., Verbruggen, B.
openaire   +4 more sources

Enhanced Hemocompatibility via Bivalirudin and Bicarbonate as Alternative to Heparin in a Catheter‐Based Axial‐Flow System

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Cardiovascular therapeutic devices typically require systemic heparin due to underlying thrombotic risk. The Impella axial flow system further relies on internal perfusion with either a heparin‐containing or sodium bicarbonate purge solution during operation.
Kaitlyn R. Ammann   +7 more
wiley   +1 more source

Use of PopPK and E‐R Analyses toward Explaining Causal Link Between ADAMTS13 in Recombinant vs. Plasma‐Based Therapies and Clinical Effects in cTTP

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra‐rare, potentially life‐threatening condition caused by a deficiency of the blood enzyme ADAMTS13. Until now, ADAMTS13 replacement has been achieved with infusions of plasma or plasma‐based therapies (PBT).
Munjal Patel   +11 more
wiley   +1 more source

Human plasma-derived FVIII/VWD concentrate (Biostate): a review of experimental and clinical pharmacokinetic, efficacy and safety data

open access: yesDrugs in Context, 2016
Human plasma-derived factor VIII/von Willebrand factor complex concentrates are used to control bleeding in patients with von Willebrand disease (VWD) or haemophilia A (HA).
Paul Harper   +4 more
doaj   +1 more source

Targeting Raised von Willebrand Factor Levels in Liver Diseases: Opening Up Newer Therapeutic Avenues

open access: yesEuropean Medical Journal Hepatology, 2020
Raised levels of the blood coagulation protein von Willebrand factor (VWF) are now recognised to be important in patients with liver disease. The markedly raised plasma VWF levels in patients with acute liver failure and acute-on-chronic liver failure ...
Ashish Goel   +5 more
doaj   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy